HSP90 and HSP70 Chaperone Proteins and Interactors in Cellular Signal Transduction

$872,254ZIAFY2025CANIH

Division Of Clinical Sciences - Nci

Investigators

Linked publications, trials & patents

Paper 38878853 Paper 38316354 Paper 37091547 Paper 36602710 Paper 35883436 Paper 35754026 Paper 35108506 Paper 35060082 Paper 34675120 Paper 34376581 Paper 33764710 Paper 33428418 Paper 32022992 Paper 31987035 Paper 30931649 Paper 30645757 Paper 29725069 Paper 29392504 Paper 29203712 Paper 29177649 Paper 28845424 Paper 27770043 Paper 27466407 Paper 27300428 Paper 27297784 Paper 27072697 Paper 26916002 Paper 26916000 Paper 26517842 Paper 26286886 Paper 26071189 Paper 26070366 Paper 26058814 Paper 25686391 Paper 24731398 Paper 24714774 Paper 24462205 Paper 24379398 Paper 24121490 Paper 24035283 Paper 23734688 Paper 23564345 Paper 23457505 Paper 23371049 Paper 23352416 Paper 23042933 Paper 22935698 Paper 22920906 Paper 22894668 Paper 22804236 Paper 22753480 Paper 22727666 Paper 22510516 Paper 22315411 Paper 22310230 Paper 22215907 Paper 22134243 Paper 22102915 Paper 21964864 Paper 21946277 Paper 21907917 Paper 21856339 Paper 21777805 Paper 21730179 Paper 21419342 Paper 21154128 Paper 21129982 Paper 21127511 Paper 20651736 Paper 20572190 Paper 20519952 Paper 20159553 Paper 20061796 Paper 19945858 Paper 19933325 Paper 19838189 Paper 19763143 Paper 19519207 Paper 19502802 Paper 19414312 Paper 19359180 Paper 19259122 Paper 19229106 Paper 19064253 Paper 18922470 Paper 18840695 Paper 18769157 Paper 18677112 Paper 18637013 Paper 18549799 Paper 18435518 Paper 18320023 Paper 17968312 Paper 17949810 Paper 17851558 Patent 9782399 Patent 9233973 Patent 8859207 Patent 7811998 Patent 7608594

Abstract

This research program was discontinued in late November 2024 with Dr. Neckers retirement from government service. He is best known for his work on the molecular chaperone Hsp90 which led to its identification and validation as a non-oncogenic target in cancer. Neckers also identified numerous oncogenic client proteins of Hsp90, findings that led to an understanding of how a single protein can be manipulated to target multiple oncogenes simultaneously. There are now over 200 known Hsp90 clients that have been identified as a result of Neckers' work, many of which are oncogenes.

View original record on NIH RePORTER →